Literature DB >> 19052781

Trans labilization of am(m)ine ligands from platinum(II) complexes by cancer cell extracts.

Yonit Kasherman1, Stefan Sturup, Dan Gibson.   

Abstract

Cisplatin, cis-[Pt(NH(3))(2)Cl(2)], is an effective anticancer agent in wide clinical use whose efficacy is affected by cellular interactions with sulfur-containing nucleophiles. These interactions can potentially enhance the efficacy of the drug by mediating its delivery to nuclear DNA or inactivate the drug by binding to it irreversibly or by labilizing the NH(3) ligands. Despite the potential importance of trans-labilization reactions in the mechanism of action of the drug, few detailed studies on trans labilization of the ammines have been conducted. We used 2D NMR to show that some trans labilization occurs in proliferating cells and that aqueous extracts of cancer cells labilized 20% of the amine ligands of cis-[PtCl(2)((13)CH(3)NH(2))(2)] after a 12-h incubation. Both low molecular mass nucleophiles (less than 3 kDa) and high molecular mass nucleophiles (more than 3 kDa) labilize the amines with similar efficiency. Studies with model compounds show that thiols and thioethers bind to platinum(II) at similar rates, but thioethers are significantly more efficient at labilizing the am(m)ine at lower pH. N-Acetylcysteine is a more efficient trans-labilizer than glutathione, suggesting that the displacement of the amine proceeds through an associative mechanism. The lag time, the time that elapses from the formation of the Pt-S bond till the release of the amine trans to the sulfur, depends on the pH (for thiols), increasing at lower pH. Quantification of the platinum adducts obtained from incubation of cisplatin with cell extracts indicates that two thirds of the platinum is bound to cellular components with molecular mass greater than 3 kDa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052781     DOI: 10.1007/s00775-008-0456-6

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  35 in total

1.  Metallothioneins and resistance to cisplatin and radiation in prostate cancer.

Authors:  David J Smith; Meena Jaggi; Wenguang Zhang; Anton Galich; Cheng Du; Samuel P Sterrett; Lynette M Smith; K C Balaji
Journal:  Urology       Date:  2006-06       Impact factor: 2.649

2.  The trans labilization of cis-[PtCl2(13CH3NH2)2] by glutathione can be monitored at physiological pH by [1H,13C] HSQC NMR.

Authors:  Dan Gibson; Yonit Kasherman; Dina Kowarski; Inna Freikman
Journal:  J Biol Inorg Chem       Date:  2005-12-10       Impact factor: 3.358

3.  Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques.

Authors:  M el-Khateeb; T G Appleton; L R Gahan; B G Charles; S J Berners-Price; A M Bolton
Journal:  J Inorg Biochem       Date:  1999-10       Impact factor: 4.155

Review 4.  Mechanisms of acquired resistance to cisplatin.

Authors:  P A Andrews
Journal:  Cancer Treat Res       Date:  1994

Review 5.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

Review 6.  Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.

Authors:  Stephen G Chaney; Sharon L Campbell; Ekaterina Bassett; Yibing Wu
Journal:  Crit Rev Oncol Hematol       Date:  2005-01       Impact factor: 6.312

7.  Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5'-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry.

Authors:  A Küng; D B Strickmann; M Galanski; B K Keppler
Journal:  J Inorg Biochem       Date:  2001-10       Impact factor: 4.155

8.  Towards a better understanding of the cisplatin mode of action.

Authors:  V Marchán; V Moreno; E Pedroso; A Grandas
Journal:  Chemistry       Date:  2001       Impact factor: 5.236

9.  Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry.

Authors:  Joanna Will; William S Sheldrick; Dirk Wolters
Journal:  J Biol Inorg Chem       Date:  2007-12-22       Impact factor: 3.358

Review 10.  Cisplatin and platinum drugs at the molecular level. (Review).

Authors:  Teni Boulikas; Maria Vougiouka
Journal:  Oncol Rep       Date:  2003 Nov-Dec       Impact factor: 3.906

View more
  7 in total

1.  Reaction of platinum(II) diamine and triamine complexes with selenomethionine.

Authors:  Kevin M Williams; Rebekkah P Dudgeon; Stephen C Chmely; Stephanie R Robey
Journal:  Inorganica Chim Acta       Date:  2011-03-15       Impact factor: 2.545

2.  In vitro and in vivo antitumor activities and DNA binding mode of five coordinated cyclometalated organoplatinum(II) complexes containing biphosphine ligands.

Authors:  Michael Frezza; Q Ping Dou; Yan Xiao; Hamidreza Samouei; Mehdi Rashidi; Fayezeh Samari; Bahram Hemmateenejad
Journal:  J Med Chem       Date:  2011-08-24       Impact factor: 7.446

3.  Use of top-down and bottom-up Fourier transform ion cyclotron resonance mass spectrometry for mapping calmodulin sites modified by platinum anticancer drugs.

Authors:  Huilin Li; Tzu-Yung Lin; Steve L Van Orden; Yao Zhao; Mark P Barrow; Ana M Pizarro; Yulin Qi; Peter J Sadler; Peter B O'Connor
Journal:  Anal Chem       Date:  2011-11-18       Impact factor: 6.986

4.  Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1.

Authors:  Zhengyi Wu; Qin Liu; Xiao Liang; Xiaoliang Yang; Ningyan Wang; Xinghao Wang; Hongzhe Sun; Yi Lu; Zijian Guo
Journal:  J Biol Inorg Chem       Date:  2009-08-08       Impact factor: 3.358

5.  Mass spectrometry evidence for cisplatin as a protein cross-linking reagent.

Authors:  Huilin Li; Yao Zhao; Hazel I A Phillips; Yulin Qi; Tzu-Yung Lin; Peter J Sadler; Peter B O'Connor
Journal:  Anal Chem       Date:  2011-06-02       Impact factor: 6.986

6.  Protein flexibility is key to cisplatin crosslinking in calmodulin.

Authors:  Huilin Li; Stephen A Wells; J Emilio Jimenez-Roldan; Rudolf A Römer; Yao Zhao; Peter J Sadler; Peter B O'Connor
Journal:  Protein Sci       Date:  2012-07-11       Impact factor: 6.725

7.  On the Heterogeneous Nature of Cisplatin-1-Methyluracil Complexes: Coexistence of Different Aggregation Modes and Partial Loss of NH3 Ligands as Likely Explanation.

Authors:  Sonja Pullen; Alexander Hegmans; Wolf G Hiller; André Platzek; Eva Freisinger; Bernhard Lippert
Journal:  ChemistryOpen       Date:  2021-01       Impact factor: 2.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.